More evidence this week of how unchecked drug price increases are forcing hospitals to make tough choices and are a serious economic threat to the patients and communities we serve. An AHA/Federation of American Hospitals-commissioned report by the University of Chicago’s NORC showed inpatient hospital drug costs increased more than 38% per admission between 2013 and 2015. An AHA infographic also outlined how rising drug prices are limiting patient access to needed medicines and are busting hospital budgets. What’s most surprising is that the list of worst offenders is dominated by old drugs, some of which have been on the market for decades. Their prices are being raised in seemingly random and unpredictable ways. When drug companies put profits before patients, we all pay the price. This is part of our overall strategy on drug pricing, which includes AHA’s membership in the Campaign for Sustainable Rx Pricing – a coalition of health care providers, insurers and seniors focused on highlighting the need for action and advocating for solutions to address the problem through greater transparency, competition and value. In fact, these ideas are consistent with our specific policy recommendations to rein in escalating drug prices, which were developed with input from member hospitals and health systems through our governance processRegardless of the outcome of the election, we will work with our coalition partners in a bipartisan manner to pursue legislation next year.  

Related News Articles

Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…